ALLMedicine™ Choroideremia Center

Jun 18th, 2022 - To assess the safety of the subretinal delivery of a recombinant adeno-associated virus serotype 2 (AAV2) vector carrying a human CHM-encoding cDNA in choroideremia (CHM). Prospective, open-label, non-randomized, dose-escalation, phase 1/2 clinica...

May 19th, 2022 - This is an open label study involving a total of 6 male patients. Screening and patient medical records will determine patient eligibility. Patients will receive a subretinal injection of the rAAV2.REP1 vector by a trained vitreoretinal surgeon in...

Apr 14th, 2022 - Rhegmatogenous retinal detachment in choroideremia is a rare occurrence. The authors present a case of a 23-year-old man with choroideremia with a near-total rhegmatogenous retinal detachment. Fundus examination did not reveal any retinal breaks, ...

Mar 25th, 2022 - This study was previously posted by NightstaRx Ltd. In October 2020, sponsorship of the trial was transferred to Biogen.

Mar 11th, 2022 - Subretinal injection for gene augmentation in retinal degenerations forcefully detaches the neural retina from the retinal pigment epithelium, potentially damaging photoreceptors and/or retinal pigment epithelium cells. To use adaptive optics scan...

May 19th, 2022 - This is an open label study involving a total of 6 male patients. Screening and patient medical records will determine patient eligibility. Patients will receive a subretinal injection of the rAAV2.REP1 vector by a trained vitreoretinal surgeon in...

Mar 25th, 2022 - This study was previously posted by NightstaRx Ltd. In October 2020, sponsorship of the trial was transferred to Biogen.

Jan 6th, 2022 - The purpose of this study is to understand the rate of progression of all stages of choroideremia using a variety of assessments performed in the clinic including visual field measures, specialized photography of the eye and participant-reported v...

Oct 27th, 2020 - Study name: THOR - Tübingen Choroideremia gene therapy trial open label Phase 2 clinical trial using an adeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1) Phase: Phase II Indication: Adult males with a clinical phenotype of ...

Oct 15th, 2014 - Primary objective: To examine the short-term effects of of simvastatin on the vision on males with choroideremia, evaluated by full-field scotopic threshold testing. The investigators hypothesize that they will see a reversible decrease in the dar...

Jul 17th, 2015 - A retinal prosthesis system can safely, effectively, and reliably restore enough visual function to patients with late-stage retinitis pigmentosa to improve object detection and overall well-being, according to findings from an international trial...

Apr 30th, 2015 - A new study shows how optical coherence tomography (OCT) angiography can be used to visualize common retinal diseases such as diabetic retinopathy, age-related macular degeneration, and choroideremia, which are major causes of blindness. Researche...

Apr 30th, 2015 - A new study shows how optical coherence tomography (OCT) angiography can be used to visualize common retinal diseases such as diabetic retinopathy, age-related macular degeneration, and choroideremia, which are major causes of blindness. Researche...

May 7th, 2014 - Advances in Vitreoretinal Disease Management Many vitreoretinal pathologies have witnessed impressive advances in their management over the past decade. Most of these advances have involved pharmacologic innovation aimed at controlling exudative d...

May 7th, 2014 - Advances in Vitreoretinal Disease Management Many vitreoretinal pathologies have witnessed impressive advances in their management over the past decade. Most of these advances have involved pharmacologic innovation aimed at controlling exudative d...